v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (167,314) $ (5,531)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation on property and equipment 30 29
Depreciation on revenue-generating equipment 14 17
Amortization of right-of-use assets 188 55
Amortization of intangible assets 1
Amortization of debt discount 147 235
Fair value of vested stock options 52 51
Fair value of vested restricted stock units 6,875 264
Fair value of common stock issued for services 5,077
Fair value of common stock issued for employee compensation 46
Loss on debt extinguishment 1,355
Loss on issuance of warrant liability 123,941
Change in fair value of warrant liability 23,161
Accrued interest (147) (47)
Changes in operating assets and liabilities:    
Accounts receivable 26 (779)
Inventories 234 2,393
Deposits for inventory (1,699) 2,052
Prepaid expenses and other current assets (160) (243)
Accounts payable (114) (594)
Accrued expenses (1,102) 956
Payroll tax liability 122
Transition agreement for former related party (52) (43)
Research and development contract liabilities 155
Customer deposits 16
Deferred revenue 1,471 1,923
Deferred grant revenue (132)
Operating lease liabilities (442) (58)
Net cash provided by (used in) operating activities (8,297) 726
CASH FLOWS FROM INVESTING ACTIVITIES:    
Cash received on reverse acquisition 12,670
Capitalized costs LiGHT proton therapy system equipment (4)
Intangible assets costs (25) (53)
Purchase of property and equipment (11)
Net cash provided by (used in) investing activities 12,630 (53)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of liability-classified warrants 1,500
Proceeds from exercise of stock options 74
Proceeds from exercise of warrants 365
Shareholders distribution on reverse acquisition (790)
Repurchase of fundamental transaction warrants (4,272)
Proceeds from debt, net of fees 12,382 555
Repayment of debt (8,099) (1,252)
Net cash provided by (used in) financing activities 1,160 (697)
NET CHANGE IN CASH    
Net increase (decrease) 5,493 (24)
Cash - Beginning of period 156 197
Cash - End of period 5,649 173
Supplemental disclosures of cash flow information:    
Cash paid for interest 788 1,104
Non-cash investing and financing activities:    
Common shares issued for loan fees 110
Common shares issued for trade accounts payable 4,200
Prepaid expenses from acquisition 129
Note settled in acquisition 6,500
LiGHT proton therapy system equipment from acquisition 6,607
Right-to-use asset, net from acquisition 742
Accounts payable from acquisition 328
Research and development contract liabilities from acquisition 231
Lease liabilities from acquisition 1,102
Reverse acquisition equity issued 118,252
Shares issued on exercise of liability-classified warrants 148,603
Issuance of common stock issued for common stock issuable 122
Payroll tax receivable and taxes payable 1,441
Exercise price receivable $ 2,050

Source